Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05490043 | A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 33 | Antengene (Hangzhou) Biologics Co., Ltd.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | terminated | Phase 1 / Phase 2 | 9 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | terminated | Phase 1 | 19 | 3B Pharmaceuticals GmbHINDUSTRY | 2 | Aug 24, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT05388877 | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma | terminated | Phase 1 | 13 | Mayo ClinicOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT02807597 | Real-time Intraoperative Breast Cancer Visualization for Margin Assessment | terminated | Phase 1 / Phase 2 | 9 | Samuel AchilefuOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03015792 | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | terminated | Phase 1 | 18 | Mayo ClinicOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05708924 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 1 | 1 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors | terminated | Phase 1 | 44 | Day One Biopharmaceuticals, Inc.INDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | terminated | Phase 1 / Phase 2 | 6 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | terminated | Phase 1 / Phase 2 | 6 | Inge Marie SvaneOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05623488 | CAR T Cells in Mesothelin-Expressing Breast Cancer | terminated | Phase 1 | 2 | University of PennsylvaniaOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). | terminated | Phase 1 | 29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | terminated | Phase 1 | 139 | Novartis PharmaceuticalsINDUSTRY | 10 | Aug 11, 2025 | clinicaltrials |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05743036 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | terminated | Phase 1 | 44 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Aug 8, 2025 | clinicaltrials |
| NCT04645797 | A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions | terminated | Phase 1 | 11 | Apros Therapeutics, IncINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04963413 | RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. | terminated | Phase 1 | 6 | University of FloridaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | terminated | Phase 1 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05369000 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer | terminated | Phase 1 | 96 | Lava TherapeuticsINDUSTRY | 3 | Aug 1, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT01309490 | Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Jewish General HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04849910 | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | terminated | Phase 1 / Phase 2 | 67 | Vor BiopharmaINDUSTRY | 2 | Jul 29, 2025 | clinicaltrials |
| NCT05984199 | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | terminated | Phase 1 / Phase 2 | 38 | Vor BiopharmaINDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06588660 | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 1 | University of WashingtonOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04904185 | ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma | terminated | Phase 1 | 8 | Inge Marie SvaneOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05817058 | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 30 | Affimed GmbHINDUSTRY | 2 | Jul 23, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04042051 | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer(Panthera) | terminated | Phase 1 | 2 | Cancer Trials IrelandNETWORK | 2 | Jul 22, 2025 | clinicaltrials |
| NCT04220229 | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | terminated | Phase 1 / Phase 2 | 6 | University of WashingtonOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 34 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT03287817 | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma(ALEXANDER) | terminated | Phase 1 / Phase 2 | 52 | Autolus LimitedINDUSTRY | 2 | Jul 14, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05209152 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia | terminated | Phase 1 | 7 | AmgenINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04789408 | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 15 | Kite, A Gilead CompanyINDUSTRY | 2 | Jul 11, 2025 | clinicaltrials |
| NCT05788926 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | terminated | Phase 1 | 22 | TransgeneINDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT03816839 | Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)(AMEERA-2) | terminated | Phase 1 | 10 | SanofiINDUSTRY | 1 | Jul 7, 2025 | clinicaltrials |
| NCT05511844 | Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | terminated | Phase 1 | 25 | Orum Therapeutics USA, Inc.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03991741 | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors | terminated | Phase 1 | 3 | Gregory DanielsOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | terminated | Phase 1 | 55 | Biomea Fusion Inc.INDUSTRY | 5 | Jul 3, 2025 | clinicaltrials |
| NCT03440437 | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 80 | invoX Pharma LimitedINDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | terminated | Phase 1 | 39 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03469011 | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. | terminated | Phase 1 | 14 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2025source: clinicaltrials